Blog
RSS FeedPosted by Michael Wonder on 15 Mar 2022
Prolonged price negotiation for Kymriah devastates leukaemia patients
15 March 2022 - Drained by dragging price negotiations between Novartis and the Government for breakthrough cancer treatment Kymriah (tisagenlecleucel), ...
Posted by Michael Wonder on 10 Mar 2022
How will reimbursement for Tecentriq in liver cancer affect biosimilars?
10 March 2022 - Roche is negotiating with the government over the reimbursement price of Tecentriq (atezolizumab), which passed the ...
Posted by Michael Wonder on 06 Mar 2022
Paediatric rare disease drug Koselugo fails to get insurance benefits
4 March 2022 - AstraZeneca’s Koselugo (selumetinib), the first rare disease treatment approved in Korea through an accelerated review due ...
Posted by Michael Wonder on 22 Feb 2022
Immunotherapy Keytruda gets insurance benefits
22 February 2022 - MSD’s anti-PD-1 immunotherapy Keytruda (pembrolizumab) obtained health insurance benefits five years after winning marketing approval to ...
Posted by Michael Wonder on 22 Feb 2022
Celltrion's auto-immune disease biosimilar wins further approval in Europe
22 February 2022 - South Korean pharmaceutical giant Celltrion said Tuesday that a high concentration version of its auto-immune disease ...
Posted by Michael Wonder on 15 Feb 2022
Drug makers lose choline alfoscerate suit against Government
15 February 2022 - A court dismissed local drug makers’ appeal to nullify the Government’s push to negotiate the recollection ...
Posted by Michael Wonder on 09 Feb 2022
HIRA mulls therapeutic outcome based benefits for ultra-expensive drugs
9 February 2022 - Pharmaceutical industry officials are paying attention to how the Korean government will manage health insurance benefits ...
Posted by Michael Wonder on 28 Jan 2022
Glaucoma drug Vyzulta, psoriasis remedy Skilarence win insurance benefit
28 January 2022 - The government granted health insurance benefits for Bausch Health Korea’s glaucoma treatment Vyzulta (latanoprostene bunod) and ...
Posted by Michael Wonder on 17 Jan 2022
Keytruda reimbursement boosts MSD’s R&D of follow-up drug
17 January 2022 - The government’s recognition of MSD’s Keytruda (pembrolizumab) for reimbursement as the first-line therapy for lung cancer ...
Posted by Michael Wonder on 17 Jan 2022
$421,000 cancer drug Kymriah becomes eligible for reimbursement
14 January 2022 - Novartis’ breakthrough cancer treatment Kymriah (ingredient: tisagenlecleucel), which costs over 500 million won (US$421,000), has become ...
Posted by Michael Wonder on 25 Nov 2021
Tagrisso, Opdivo fail to get broader reimbursement
25 November 2021 - AstraZeneca Korea’s non-small-cell lung cancer treatment Tagrisso (osimertinib) and Ono Pharma Korea’s immunotherapy Opdivo (nivolumab) failed ...
Posted by Michael Wonder on 10 Nov 2021
KRPIA raises concern over HIRA’s cost effectiveness evaluation plan
10 November 2021 - Korea Research-based Pharma Industry Association (KRPIA) expressed concerns over HIRA's plan of evaluating a drug’s cost ...
Posted by Michael Wonder on 14 Oct 2021
Drug pricing tug of war expected over CAR-T therapy Kymriah
14 October 2021 - The world’s first CAR-T therapy, Kymriah (tisagenlecleucel), passed the review of a panel at the Health ...
Posted by Michael Wonder on 11 Oct 2021
Takeda's ovarian cancer drug Zejula gets expanded insurance benefit
1 October 2021 - Takeda Korea said its ovarian cancer treatment Zejula would receive expanded health insurance coverage as maintenance ...
Posted by Michael Wonder on 28 Sep 2021
A review of utility measurement methods used in pharmacoeconomic submissions to HIRA in South Korea: methodological consistency and areas for improvement
28 September 2021 - This study, which was conducted as part of a project for revision of the pharmacoeconomic ...